Banca de DEFESA: JOSÉ SOUSA DE ALMEIDA JÚNIOR

Uma banca de DEFESA de DOUTORADO foi cadastrada pelo programa.
STUDENT : JOSÉ SOUSA DE ALMEIDA JÚNIOR
DATE: 17/08/2023
TIME: 14:00
LOCAL: Auditório NTB
TITLE:

PRE-CLINICAL STUDIES ON THE SAFETY AND EFFECTIVENESS OF ANDIROBA, COPAIBA AND JUCA FOR THE DEVELOPMENT OF A PHYTOMEDICATION

KEY WORDS:

Copaifera reticulata, Carapa guianensis, Libidibia ferrea, juca, copaiba, andiroba, cicatrization, inflammation, antimicrobial

PAGES: 194
BIG AREA: Ciências Biológicas
AREA: Farmacologia
SUMMARY:

The search for natural products with Amazonian species that act on healing, infection and inflammation reduction corresponds to a very widespread area of research. In the Amazon, there are several popularly known products due to their therapeutic potential, such as Carapa guianensis (andiroba), Copaifera reticulata (copaíba) and Libidibia ferrea (jucá), which in areas of difficult access are often used as first-choice remedies. an alternative to the shortage of medicines. In addition to the therapeutic application, these products have also been reported as part of numerous products, such as cosmetics, among others. Thus, it is known that ethnopharmacology gave rise to several pharmaceutical products that exist today, whether they are herbal medicines or as a base product in the construction of allopathic drugs. Such products, today complement the day-to-day in drugstores throughout the country, which include numerous therapeutic indications, such as anxiolytic, combating varicose veins, inflammation, infection, food supplement, etc. In the field of inflammation, there are already anti-inflammatory ointments based on natural products that are widely publicized commercially, which even have Beta-caryophyllene as a main constituent, which is also one of the major constituents of copaibas. Therefore, we decided to study the pharmacological synergism of the three natural products most used by traditional Amazonian populations associated in a single topical formulation, proving the safety and efficacy of the possible new commercial medicine. In order to evaluate the safety of the product, several tests recommended by renowned institutions (ANVISA and OECD) will be applied. To prove the therapeutic efficacy of the drug, the healing, anti-inflammatory and antimicrobial effects will be evaluated. To achieve these objectives, the collection, botanical identification and chemical characterization of the studied species will be carried out, together with the determination of acute oral toxicity, acute dermal toxicity, repeated dose toxicity, in vitro skin irritation, in vitro eye irritation/corrosion, sensitivity dermal, cytotoxic activity, research of healing, anti-inflammatory and antimicrobial activity.

COMMITTEE MEMBERS:
Presidente - ***.758.687-** - LAURO EUCLIDES SOARES BARATA - UFOPA
Interno - 1834385 - WALDINEY PIRES MORAES
Interno - 1843993 - ANTONIO HUMBERTO HAMAD MINERVINO
Interno - 1190535 - JARSEN LUIS CASTRO GUIMARAES
Externa ao Programa - 3304272 - RAYANNE ROCHA PEREIRA - UFOPAExterno ao Programa - 1496075 - BRUNO ALEXANDRE DA SILVA - UFOPAExterna ao Programa - 2171514 - TANIA MARA PIRES MORAES - UFOPAExterno à Instituição - TIAGO SILVEIRA FERRERA - UEPA